COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according to the Cleveland Clinic. It’s a condition often linked to obesity, ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

A study published in Cell Metabolism looks at the effects of semaglutide on skeletal muscle mass in mice. Prof Lora Heisler, Director of Research, Rowett Institute, University of Aberdeen, Rowett ...

New lawsuits target pharmacies producing compounded versions of semaglutide ‘under the fake guise of personalization,’ the Danish drugmaker said ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Noom claims its microdose approach allows users to lose up to 11 pounds (around 5kg) in one month and up to 17 pounds in two ...